BindingDB logo
myBDB logout

43 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28280261 84 Non-kinase targets of protein kinase inhibitors.EBI The University of Sydney
26914985 124 Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.EBI Boehringer Ingelheim RCV GmbH & Co KG
26735842 27 Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.EBI Centre National de la Recherche Scientifique (CNRS)
26367539 22 New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.EBI University of Dundee
26043365 41 Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.EBI University of Z£rich
26230603 176 Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.EBI GlaxoSmithKline
26022843 39 Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.EBI AMRI
26155854 125 Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors.EBI GlaxoSmithKline
26080064 141 Structure-Based Design of┐-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.EBI University of Michigan
25559428 38 Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.EBI Shanghai Institute of Materia Medica
25249180 146 The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.EBI GlaxoSmithKline
24090311 12 Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.EBI The Institute of Cancer Research
24015967 71 Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.EBI GlaxoSmithKline
22726925 216 Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI Cellzome Ltd
22924434 4 Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.EBI University of Oxford
22437115 66 Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).EBI GlaxoSmithKline
22136469 148 Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.EBI GlaxoSmithKline
21568322 16 Discovery and characterization of small molecule inhibitors of the BET family bromodomains.EBI GlaxoSmithKline
22316554 22 Development of live-cell imaging probes for monitoring histone modifications.EBI Japan Science and Technology Agency
22136404 9 Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.EBI GlaxoSmithKline
21851057 30 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.EBI University of Oxford
30268702 66 Discovery and lead identification of quinazoline-based BRD4 inhibitors.EBI National Institutes of Health
28339196 48 Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.EBI University of Michigan Comprehensive Cancer Center
29678460 71 Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.EBI AbbVie Inc.
29656650 151 Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.EBI University of Strathclyde
29169673 115 Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.EBI WuXi AppTec Co., Ltd.
28463487 185 Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.EBI University of Michigan
29170024 45 Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.EBI St. Jude Children's Research Hospital
29649741 56 Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.EBI University of Texas Medical Branch
30015487 96 Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.EBI TBA
29259751 142 Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.EBI Walter and Eliza Hall Institute of Medical Research
28195723 94 Drug Discovery Targeting Bromodomain-Containing Protein 4.EBI University of Texas Medical Branch
28268136 130 Methylpyrrole inhibitors of BET bromodomains.EBI AbbVie Inc
29172540 65 Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.EBI Sichuan University
28949521 88 Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.EBI AbbVie Inc
1321744 14 Multiple histamine receptors: properties and functional characteristics.BDB Queen's Medical Centre
19138846 23 Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.BDB GSK
16386899 13 Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.BDB Hawaii Biotech Inc.